Clinical Trial Update: A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, duration of response, and safety of Xolair (omalizumab) in patients with chronic idiopathic urticaria/chronic spontaneous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria
• Spontaneous Urticaria

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Idiopathic Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2013-09-02